Wednesday, May 08 2024
12:00 PM – 07:00 PM ET - Exhibit Hall
450: Anellovectors: Expanding the Payload Capacity of Anellovirus-Based Vectors Beyond the Wild-Type Genome Capacity
Cato Prince
Ring Therapeutics
Disclosures: C. Prince: 1; Commercial Interest i.e. Company X; Ring Therapeutics. 1; What was received? i.e. Honorarium; stocks & salary. 1; For what role? i.e. Speaker; Employment.
Related Abstract